Is HSDB 3929 Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use HSDB 3929? Is HSDB 3929 safe for nursing mother and child? Does HSDB 3929 extracts into breast milk? Does HSDB 3929 has any long term or short term side effects on infants? Can HSDB 3929 influence milk supply or can HSDB 3929 decrease milk supply in lactating mothers?

• DrLact safety Score for HSDB 3929 is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of HSDB 3929 may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that HSDB 3929 may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using HSDB 3929 .
• It is recommended to evaluate the advantage of not breastfeeding while using HSDB 3929 Vs not using HSDB 3929 And continue breastfeeding.
• While using HSDB 3929 Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Retinoid which is a synthetic derivative of vitamin A. It is a cis-configuration of Tretinoin, an acid form of vitamin A.Indicated in the treatment of severe forms of acne. At latest update no published data on excretion into breast milk were found. Despite of a high plasma protein-binding capacity, it is a highly lipophilic substance, hence, it is presumed to accumulate in breastmilk. The natural form of vitamin A is readily excreted into breastmilk. In addition to being a potent teratogen (Shirazi 2015), which affects pregnancy, it has been shown to decrease all pituitary hormones levels (Karadag 2011 and 2015) along with other potential serious side effects associated to the use of HSDB 3929. It may cause galactorrhea (Larsen 1985). A safer alternative should be preferred until more published data on this drug related to breastfeeding is available, especially during the neonatal period and in case of prematurity.

No information is available on the use of HSDB 3929 during breastfeeding. Various topical agents that are less likely to be absorbed by the mother may be preferred during breastfeeding, especially while nursing a newborn or preterm infant.

A woman who had weaned her infant 18 months previously developed a nipple discharge from her right breast after 5.5 months of therapy with HSDB 3929. Microbiological, hormonal (including prolactin), radiologic, and physical examinations were otherwise normal. One month after discontinuing HSDB 3929, the discharge ceased. After HSDB 3929 was reinstituted at the same dose, the discharge reappeared within 10 days.[1] The galactorrhea was probably caused by HSDB 3929. A review of adverse reaction reports on retinoids causing a breast reaction submitted to a French pharmacovigilance center found 22 cases of gynecomastia was associated with HSDB 3929 use. Fourteen of the cases were gynecomastia, 6 were galactorrhea and 2 were of both gynecomastia and galactorrhea. Gynecomastia and/or galactorrhea was unilateral for almost half of the reported retinoid cases. The median time of onset was 90 days (IQR 39 to 347 days). The outcome was known for 27 of 31 patients and a total recovery after withdrawal of retinoid was observed for 63% of them.[2]